A Northwestern Medicine clinical trial led by Rod Passman, MD, could improve the way we care for millions of people with atrial fibrillation, but it is facing an unexpected challenge. There has been a pause in federal funding to Northwestern University that could impact this study's progress. While the trial has not been ordered to stop, all National Institutes of Health funding to Northwestern University has been frozen, raising questions about how long this potential life-saving work can go on without a resolution.